See the other short continuing and professional education courses in the Faculty of Law Legal Academy.
Cancelled: Health pandemics and IP rights: a blessing or a curse for access?
Course description
COVID-19 provides a very good template for what we can expect to happen in case of health pandemics in relation to the development of new therapeutics and vaccines. The COVID-19 crisis has led to massive public R&D investments into the development of therapeutics and vaccines, further innovation incentives in the form of Advanced Purchase Agreements (APAs), and a structural use by life science companies of patents, trade secrets and data and market exclusivity, with a view to solidify proprietary positions in the much-needed medical innovations.
This course updates you on which therapeutics and vaccines are and will be protected by intellectual property (IP) rights and data exclusivity and which pandemic related technologies we can reasonably expect to see protected in the (near) future. It will further critically discuss the generous public R&D funding as an innovation push incentive and the use of APAs as an innovation pull incentive.
Finally, the course will provide critical insight into how other legal and policy frameworks can impact the exercise of these exclusive rights and the use of innovation incentives to influence access to these medical technologies. Based on the current challenges associated with global access to much needed vaccines and therapeutics, we need a basis to understand what it means for health care systems and national budgets to achieve a better balance between public, private, and individual interests.
The course directors are experts in the area of legal protection of biomedical innovations, and have, besides a solid academic track record, also many years of experience in private practice in the areas relevant to this course.
This course will be taught in English.
At the end of this course, participants will be able to:
- Identify and understand which therapeutics and vaccine technologies will likely be protected by exclusive rights;
- Discuss and draft proposals as to how push innovation incentive R&D agreements can be improved in the context of access;
- Discuss and draft proposals as to how pull incentive APAs can be improved to guarantee access;
- Critically discuss and formulate opinions on the balance between public, private, and individual interests in pharmaceutical research and innovation.
Lawyers and patent attorneys in private practice (law firms and patent attorney firms), in-house legal and/or patent counsel of pharmaceutical and biotech companies, judges, employees at the Danish Lægemiddelstyrelsen and Sundhedsstyrelsen who deal with aspects of therapeutics and vaccines regulation and provision, academics who want to update themselves on this very topical subject, and any other civil servants at ministries for whom the subject of this course is relevant.
The final program and any course materials will be available a week before the course is held.
If you have any questions, please contact evu@jur.ku.dk
Del denne side på
Facts about the course Health pandemics and IP rights: a blessing or a curse for access?
Price for participation is DKK 2000 exclusive of VAT
Certificate of attendance: Certificate of attendance for three lessons will be issued after the course based on documented participation.
Registration no later than 9 April 2021 at 12:00 via this link.